Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate

Int Urol Nephrol. 2022 Jan;54(1):89-95. doi: 10.1007/s11255-021-03070-8. Epub 2021 Nov 19.

Abstract

Aim: To compare cancer-specific mortality (CSM) rates between radical prostatectomy (RP) vs. external beam radiotherapy (RT) in patients with ductal carcinoma (DC) of the prostate.

Materials and methods: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2016), we identified 369 DC patients, of whom 303 (82%) vs. 66 (18%) were treated with RP vs. RT, respectively. Kaplan-Meier plots and uni- and stepwise multivariate Cox regression models addressed CSM in the unmatched population. After propensity score matching (PSM) and inverse probability of treatment weighting (IPTW), Kaplan-Meier curve and Cox regression models tested the effect of RP vs RT on CSM.

Results: Overall, RT patients were older, harbored higher PSA values, higher clinical T and higher Gleason grade groups. 5-year CSM rates were respectively 4.2 vs. 10% for RP vs. RT (HR 0.40, 95% CI 0.16-0.99, p = 0.048, favoring RP). At step-by-step multivariate Cox regression, after adding possible confounders, the central tendency of the HR for RP vs. RT approached 1. PSM resulted into 124 vs. 53 patients treated respectively with RP vs. RT. After PSM, as well as after IPTW, the protective effect of RP was no longer present (HR 1.16, 95% CI 0.23-5.73, p = 0.9 and 0.97, 95% CI 0.35-2.66, p = 0.9, respectively).

Conclusions: Although CSM rate of ductal carcinoma RP patients is lower of that of RT patients, this apparent benefit disappears after statistical adjustment for population differences.

Keywords: Ductal carcinoma; External beam radiotherapy; Prostate cancer; Radical prostatectomy.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Carcinoma, Ductal / mortality*
  • Carcinoma, Ductal / radiotherapy
  • Carcinoma, Ductal / therapy*
  • Humans
  • Male
  • Middle Aged
  • Prostatectomy / methods
  • Prostatic Neoplasms / mortality*
  • Prostatic Neoplasms / radiotherapy
  • Prostatic Neoplasms / therapy*
  • Retrospective Studies
  • Survival Rate